Q-omics provides the consensus-scored TTC39C profile across patient tissues and cancer cell-line models. TTC39C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTC39C is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, TTC39C RNA expression shows 19,071 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where TTC39C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC39C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC39C survival associations across molecular data types. TTC39C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC39C RNA expression–survival associations across cancer types. High TTC39C expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, BRCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTC39C RNA expression.
This table summarizes TTC39C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC39C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC39C shows lower tumor expression in CHOL and higher tumor expression in LUAD, KIRC, COAD, LUSC and KIRP. The LUAD box plot shows higher TTC39C RNA expression in tumor versus normal tissue (log2 FC = +1.633, t-test p < 0.001).
This table shows molecular features associated with TTC39C in patient tissues and cancer cell lines. In patient samples, TTC39C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC39C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
